company background image
GNS

GenusLSE:GNS Stock Report

Market Cap

UK£3.2b

7D

-7.3%

1Y

20.0%

Updated

29 Nov, 2021

Data

Company Financials +
GNS fundamental analysis
Snowflake Score
Valuation0/6
Future Growth3/6
Past Performance2/6
Financial Health6/6
Dividends0/6

GNS Stock Overview

Genus plc operates as an animal genetics company in North America, Latin America, the United Kingdom, rest of Europe, the Middle East, Russia, Africa, and Asia.

Price History & Performance

Summary of all time highs, changes and price drops for Genus
Historical stock prices
Current Share PriceUK£49.94
52 Week HighUK£63.10
52 Week LowUK£38.96
Beta0.10
1 Month Change-9.69%
3 Month Change-15.86%
1 Year Change20.05%
3 Year Change110.01%
5 Year Change175.76%
Change since IPO3,599.26%

Recent News & Updates

Oct 29
With EPS Growth And More, Genus (LON:GNS) Is Interesting

With EPS Growth And More, Genus (LON:GNS) Is Interesting

Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...

Oct 14
Here's Why Genus (LON:GNS) Can Manage Its Debt Responsibly

Here's Why Genus (LON:GNS) Can Manage Its Debt Responsibly

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

Shareholder Returns

GNSGB BiotechsGB Market
7D-7.3%-4.8%-3.0%
1Y20.0%24.6%11.6%

Return vs Industry: GNS underperformed the UK Biotechs industry which returned 24.6% over the past year.

Return vs Market: GNS exceeded the UK Market which returned 11.6% over the past year.

Price Volatility

Is GNS's price volatile compared to industry and market?
GNS volatility
GNS Average Weekly Movement4.7%
Biotechs Industry Average Movement5.9%
Market Average Movement4.9%
10% most volatile stocks in GB Market9.7%
10% least volatile stocks in GB Market2.5%

Stable Share Price: GNS is not significantly more volatile than the rest of UK stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: GNS's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19943,400Stephen Wilsonhttps://www.genusplc.com

Genus plc operates as an animal genetics company in North America, Latin America, the United Kingdom, rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Genus Research and Development. It sells sows, boars, and semen to breed pigs with various characteristics for pork production under the PIC brand.

Genus Fundamentals Summary

How do Genus's earnings and revenue compare to its market cap?
GNS fundamental statistics
Market CapUK£3.20b
Earnings (TTM)UK£47.30m
Revenue (TTM)UK£574.30m

68.6x

P/E Ratio

5.6x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
GNS income statement (TTM)
RevenueUK£574.30m
Cost of RevenueUK£342.10m
Gross ProfitUK£232.20m
ExpensesUK£184.90m
EarningsUK£47.30m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)0.73
Gross Margin40.43%
Net Profit Margin8.24%
Debt/Equity Ratio24.8%

How did GNS perform over the long term?

See historical performance and comparison

Dividends

0.6%

Current Dividend Yield

44%

Payout Ratio

Valuation

Is Genus undervalued compared to its fair value and its price relative to the market?

68.58x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: GNS (£49.94) is trading above our estimate of fair value (£28.25)

Significantly Below Fair Value: GNS is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: GNS is poor value based on its PE Ratio (68.6x) compared to the UK Biotechs industry average (63.1x).

PE vs Market: GNS is poor value based on its PE Ratio (68.6x) compared to the UK market (19.2x).


Price to Earnings Growth Ratio

PEG Ratio: GNS is poor value based on its PEG Ratio (5.1x)


Price to Book Ratio

PB vs Industry: GNS is overvalued based on its PB Ratio (6.5x) compared to the GB Biotechs industry average (6.3x).


Future Growth

How is Genus forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

13.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: GNS's forecast earnings growth (13.3% per year) is above the savings rate (0.9%).

Earnings vs Market: GNS's earnings (13.3% per year) are forecast to grow faster than the UK market (12.3% per year).

High Growth Earnings: GNS's earnings are forecast to grow, but not significantly.

Revenue vs Market: GNS's revenue (6.7% per year) is forecast to grow faster than the UK market (4.9% per year).

High Growth Revenue: GNS's revenue (6.7% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: GNS's Return on Equity is forecast to be low in 3 years time (12.3%).


Past Performance

How has Genus performed over the past 5 years?

-4.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: GNS has a large one-off loss of £14.1M impacting its June 30 2021 financial results.

Growing Profit Margin: GNS's current net profit margins (8.2%) are higher than last year (6.4%).


Past Earnings Growth Analysis

Earnings Trend: GNS's earnings have declined by 4.6% per year over the past 5 years.

Accelerating Growth: GNS's earnings growth over the past year (34%) exceeds its 5-year average (-4.6% per year).

Earnings vs Industry: GNS earnings growth over the past year (34%) underperformed the Biotechs industry 50.7%.


Return on Equity

High ROE: GNS's Return on Equity (9.4%) is considered low.


Financial Health

How is Genus's financial position?


Financial Position Analysis

Short Term Liabilities: GNS's short term assets (£231.7M) exceed its short term liabilities (£142.5M).

Long Term Liabilities: GNS's short term assets (£231.7M) exceed its long term liabilities (£211.9M).


Debt to Equity History and Analysis

Debt Level: GNS's net debt to equity ratio (15.6%) is considered satisfactory.

Reducing Debt: GNS's debt to equity ratio has reduced from 32.9% to 24.8% over the past 5 years.

Debt Coverage: GNS's debt is well covered by operating cash flow (54.7%).

Interest Coverage: GNS's interest payments on its debt are well covered by EBIT (13.1x coverage).


Balance Sheet


Dividend

What is Genus's current dividend yield, its reliability and sustainability?

0.60%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: GNS's dividend (0.6%) isn’t notable compared to the bottom 25% of dividend payers in the UK market (1.38%).

High Dividend: GNS's dividend (0.6%) is low compared to the top 25% of dividend payers in the UK market (4.15%).


Stability and Growth of Payments

Stable Dividend: GNS is not paying a notable dividend for the UK market, therefore no need to check if payments are stable.

Growing Dividend: GNS is not paying a notable dividend for the UK market, therefore no need to check if payments are increasing.


Current Payout to Shareholders

Dividend Coverage: GNS is not paying a notable dividend for the UK market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of GNS's dividend in 3 years as they are not forecast to pay a notable one for the UK market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.5yrs

Average management tenure


CEO

Stephen Wilson (61 yo)

2.17yrs

Tenure

UK£2,888,000

Compensation

Mr. Stephen Wilson serves as Chief Executive Officer and Executive Director of Genus plc since September 13, 2019. Mr. Wilson served as Group Finance Director of Genus plc since March 1, 2013 until Septemb...


CEO Compensation Analysis

Compensation vs Market: Stephen's total compensation ($USD3.84M) is above average for companies of similar size in the UK market ($USD1.75M).

Compensation vs Earnings: Stephen's compensation has increased by more than 20% in the past year.


Leadership Team

Experienced Management: GNS's management team is considered experienced (4.5 years average tenure).


Board Members

Experienced Board: GNS's board of directors are considered experienced (3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: GNS insiders have sold more shares than they have bought in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Genus plc's employee growth, exchange listings and data sources


Key Information

  • Name: Genus plc
  • Ticker: GNS
  • Exchange: LSE
  • Founded: 1994
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: UK£3.202b
  • Shares outstanding: 64.95m
  • Website: https://www.genusplc.com

Number of Employees


Location

  • Genus plc
  • Matrix House
  • Basing View
  • Basingstoke
  • Hampshire
  • RG21 4DZ
  • United Kingdom

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/11/29 22:57
End of Day Share Price2021/11/29 00:00
Earnings2021/06/30
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.